GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Employees - 3,
CEO - Dr. W. Marc Hertz Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 0.76M
Altman ZScore(max is 10): 10.84, Piotroski Score(max is 10): 1, Working Capital: $911000, Total Assets: $5739000, Retained Earnings: $58467000, EBIT: -8229000, Total Liabilities: $1707000, Revenue: $4912000
AryaFin Target Price - $15.72 - Current Price $1.44 - Analyst Target Price $170.00
| Ticker | GRI |
| Index | - |
| Curent Price | 1.44 |
| Change | -13.77% |
| Market Cap | 0.76M |
| Average Volume | 258.09K |
| Income | -10.12M |
| Sales | 0.00M |
| Book Value/Share | 7.67 |
| Cash/Share | 9.55 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 4 |
| Moving Avg 20days | -73.94% |
| Moving Avg 50days | -80.87% |
| Moving Avg 200days | -89.04% |
| Shares Outstanding | 0.53M |
| Earnings Date | Feb 26 |
| Inst. Ownership | 2.51% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 0.19 |
| Price/Cash | 0.15 |
| Price/FCF | - |
| Quick Ratio | 3.43 |
| Current Ratio | 3.43 |
| Debt/Equity | 0.03 |
| Return on Assets | -188.80% |
| Return on Equity | -382.57% |
| Return on Investment | -246.62% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 20.81 |
| BETA(β) | -1.72 |
| From 52week Low | -10.00% |
| From 52week High | -98.90% |
| EPS | -203.36 |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | 70.23% |
| Sales past 5 Year | -20.00% |
| EPS Y/Y | 98.55% |
| Sales Y/Y | - |
| EPS Q/Q | 98.93% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | 8.22% |
| ATR(14) | 1.56 |
| Perf Week | -75.47% |
| Perf Month | -79.22% |
| Perf Quarter | -89.77% |
| Perf Year | -98.82% |
| Perf YTD | -89.77% |
| Target Price | 170.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer